ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1892

Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis

siddharth Agrawal1, Freya Shah1, Ritu Tated2, Radhe Shah3 and Mahir Modi4, 1landmark medical center, cumberland, RI, 2New York Medical College, Vallaha, 3Beth Israel Deaconess Medical Center, Boston, 4GCS Medical College, hospital and Research Centre, Ahmedabad, India

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1877–1913) Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention (PCI) remains understudied. We aimed to evaluate in-hospital outcomes in SLE patients undergoing PCI.

Methods: We performed a retrospective analysis of the National Inpatient Sample from 2016 to 2022, identifying adult patients who underwent PCI. Patients were stratified based on the presence or absence of SLE. Multivariate logistic regression models adjusted for demographics, comorbidities, and hospital characteristics were used to assess outcomes. The primary outcome was in-hospital mortality; secondary outcomes included stroke, atrial fibrillation, heart failure, and bleeding complications.

Results: Of 3,132,560 PCI hospitalizations, 12,765 (0.4%) involved patients with SLE. Compared with non-SLE patients, SLE patients were younger, more likely to be female (78.7% vs 32.5%), and more often Black (23.5% vs 9.6%) (all p < 0.001). SLE patients had a higher prevalence of hypertension, anemia, chronic kidney disease, peripheral arterial disease, and coagulation disorders. There was no significant difference in adjusted in-hospital mortality between groups (OR 0.954, 95% CI 0.856–1.063, p=0.391). However, SLE was associated with higher odds of stroke (OR 1.407, 95% CI 1.348–1.474, p < 0.001), atrial fibrillation (OR 1.078, 95% CI 1.022–1.136, p=0.005), and bleeding complications (OR 1.147, 95% CI 1.051–1.253, p=0.002). No significant difference was observed in the incidence of heart failure.

Conclusion: Among patients undergoing PCI, SLE is associated with increased risks of stroke, atrial fibrillation, and bleeding, but similar in-hospital mortality compared to non-SLE patients. Focused risk mitigation strategies may improve outcomes in this high-risk population.

Supporting image 1Table 1. Baseline Characteristics of Patients Undergoing PCI, Stratified by SLE Status

Supporting image 2Table 2. Adjusted In-Hospital Outcomes for SLE vs Non-SLE Patients Undergoing PCI


Disclosures: s. Agrawal: None; F. Shah: None; R. Tated: None; R. Shah: None; M. Modi: None.

To cite this abstract in AMA style:

Agrawal s, Shah F, Tated R, Shah R, Modi M. Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-systemic-lupus-erythematosus-on-in-hospital-outcomes-following-percutaneous-coronary-intervention-insights-from-a-7-year-nationwide-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-systemic-lupus-erythematosus-on-in-hospital-outcomes-following-percutaneous-coronary-intervention-insights-from-a-7-year-nationwide-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology